09:48 AM EDT, 09/10/2025 (MT Newswires) -- NeOnc Technologies ( NTHI ) said Wednesday the US Food and Drug Administration has authorized the company to proceed with a multi-phase 2 clinical trial of NEO212-01 to treat brain cancer.

The biopharmaceutical company said an independent review of the recommended dose in the study is ongoing and that it expects enrollment to begin before the end of the year. It also said it believes NEO212 could potentially replace Temozolomide as the standard of care for all brain cancers.

Price: 8.42, Change: -0.06, Percent Change: -0.71